Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Published

Journal Article

Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. This chapter will provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.

Full Text

Duke Authors

Cited Authors

  • Badesch, DB; Abman, SH; Ahearn, GS; Barst, RJ; McCrory, DC; Simonneau, G; McLaughlin, VV; American College of Chest Physicians,

Published Date

  • July 1, 2004

Published In

Volume / Issue

  • 126 / 1 Suppl

Start / End Page

  • 35S - 62S

PubMed ID

  • 15249494

Pubmed Central ID

  • 15249494

Electronic International Standard Serial Number (EISSN)

  • 1931-3543

International Standard Serial Number (ISSN)

  • 0012-3692

Digital Object Identifier (DOI)

  • 10.1378/chest.126.1_suppl.35s

Language

  • eng